The recall affects two lots of 50 milligram strength and four lots of 100 milligram strength.
The recall is a result of the detection of N-Nitroso-N-methyl-4-aminobutyric acid, a potentially carcinogenic impurity.
The impurity was detected in one lot of an active pharmaceutical ingredient made by Hetero Labs. This active ingredient was then used by Teva to manufacturer six bulk lots of the tablets.
The bulk lots were sold to Golden State Medical Supply, which packaged these products under its own label and distributed bottles of 30, 90 and 1,000 tablets to their customers.
Read the full recall announcement here.
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
